Off-Label Use of Omalizumab in Pediatric Anaphylaxis

Journal of Allergy and Clinical Immunology - United States
doi 10.1016/j.jaci.2018.12.692
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Off-Label Use of Rituximab in Refractory Pediatric Rheumatic Diseases: A Single-Center Experience

Pediatric Rheumatology
ImmunologyPediatricsRheumatologyAllergyPerinatologyChild Health
2014English

Letter to the Editor: Off-Label rhBMP-2 Use in Pediatric Spine Deformity Surgery

Journal of Neurosurgery: Pediatrics
Child HealthPerinatologyNeurologyMedicinePediatricsSurgery
2015English

«Off Label Use»: Nouvelles Recommandations

Bulletin des Médecins Suisses
2007English

Off-Label Use of Approved Drugs

Nature Reviews Clinical Oncology
Oncology
2009English

Omalizumab in the Prevention of Anaphylaxis During Immunotherapy: A

Postepy Dermatologii I Alergologii
DermatologyAllergyImmunology
2014English

Off-Label Drug Use in Hospitalized Children

Archives of Pediatrics & Adolescent Medicine
2007English

Methylphenidate Off-Label Use and Safety

SpringerPlus
Multidisciplinary
2014English

Off-Label Use in Lymphoma Patients in Switzerland

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Off-Label Use of Rituximab in Dermatology: Pemphigus Treatment

Anais Brasileiros de Dermatologia
Dermatology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy